From Joe's FB page: https://nugenerexio.com/
Post# of 36537
(Total Views: 337)
Posted On: 03/07/2021 8:21:00 AM
From Joe's FB page:
https://nugenerexio.com/
Ii-Key vaccines hijack the immune system through antigen presenting cells; protecting us against foreign invaders.
NuGenerex Immuno-Oncology is focused on the modulation of the immune system and activation of T cells to treat cancer. To that end, we are developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (“MHC”) Class II associated invariant chain (Ii) that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response.
T cells recognize antigenic epitopes when they are ‘presented’ to them by specific molecules, termed (MHC) on the surface of infected or malignant cells. This interaction activates the T cells with a Th1 response that stimulates a multicellular cascade of actions to eliminate the diseased cell and protect against future disease recurrence.
We have developed a number of Ii-Key peptide vaccines for the immunotherapeutic targeting of tumor associated antigens (TAAs) in cancer and for vaccines against infectious diseases.
Ii-Key peptide vaccines can also be used to selectively activate Th2 responses and thereby induce tolerance to antigens involved in harmful immune reactions, with therapeutic applications in major market segments including diabetes, arthritis, allergy, transplant rejection, and other autoimmune diseases.
NGIO was created not only to advance the Ii-Key core technology, but also to expand our portfolio in the field of immunotherapy, infectious disease vaccines and personalized medicine through partnerships and acquisitions.
How the Ii-Key Works – The Complete Vaccine Solution
Technology Platform
T cells recognize antigenic epitopes when they are ‘presented’ to them by specific molecules, termed (MHC) on the surface of infected or malignant cells. This interaction activates the T cells, stimulating a multicellular cascade of actions that eliminates the diseased cell and protects against future disease recurrence.
Ii-Key Mechanism of Immune System Modulation:
CD4 Activation, T Cell Response, Antibody Induction, Immunologic Memory
https://nugenerexio.com/
Ii-Key vaccines hijack the immune system through antigen presenting cells; protecting us against foreign invaders.
NuGenerex Immuno-Oncology is focused on the modulation of the immune system and activation of T cells to treat cancer. To that end, we are developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (“MHC”) Class II associated invariant chain (Ii) that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response.
T cells recognize antigenic epitopes when they are ‘presented’ to them by specific molecules, termed (MHC) on the surface of infected or malignant cells. This interaction activates the T cells with a Th1 response that stimulates a multicellular cascade of actions to eliminate the diseased cell and protect against future disease recurrence.
We have developed a number of Ii-Key peptide vaccines for the immunotherapeutic targeting of tumor associated antigens (TAAs) in cancer and for vaccines against infectious diseases.
Ii-Key peptide vaccines can also be used to selectively activate Th2 responses and thereby induce tolerance to antigens involved in harmful immune reactions, with therapeutic applications in major market segments including diabetes, arthritis, allergy, transplant rejection, and other autoimmune diseases.
NGIO was created not only to advance the Ii-Key core technology, but also to expand our portfolio in the field of immunotherapy, infectious disease vaccines and personalized medicine through partnerships and acquisitions.
How the Ii-Key Works – The Complete Vaccine Solution
Technology Platform
T cells recognize antigenic epitopes when they are ‘presented’ to them by specific molecules, termed (MHC) on the surface of infected or malignant cells. This interaction activates the T cells, stimulating a multicellular cascade of actions that eliminates the diseased cell and protects against future disease recurrence.
Ii-Key Mechanism of Immune System Modulation:
CD4 Activation, T Cell Response, Antibody Induction, Immunologic Memory
(4)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼